Table 2.
CVD Endpoint Trials of Intensive Glucose Control in Diabetes
| DCCT/EDIC20 | UKPDS21 | ACCORD22 | ADVANCE23 | VADT24 | |
|---|---|---|---|---|---|
| Subjects | 1,394 T1DM | 3,867 T2DM | 10,251 T2DM | 11,140 T2DM | 1,791 T2DM |
| Age (years) | 27 | 53 | 62 | 66 | 60 |
| Follow-up (years) | 17 | 5.0 | 3.4 | 4.9 | 5.6 |
| Targets | glyco < 6.05% | FPG < 6mmol/L vs. Std |
glyco < 6% vs. 7-7.9% |
glyco < 6.5 vs. >6.5% |
glyco < 6%, 1.5% absolute reduction |
| glucose 70-120 pre- meal or <180mg/dl post-meal |
|||||
|
Duration
diabetes (years) |
6 | 0 | 10 | 7 | 10 |
| CVD (%) | 0 | 2 | 35 | 32 | 40 |
|
Baseline BP
mmHg |
115/73 | 135/82 | 136/75 | 145/81 | 132/76 |
| Baseline LDL | 109mg/dl | 3.5mmol/L | 2.7mmol/L | 3.1mmol/L | 2.8mmol/L |
|
Baseline glyco
(%) |
9.1 | 7.1 | 8.3 | 7.5 | 9.4 |
|
Result with
Intensive Control |
42% Reduction CVD (p = 0.02) |
No difference | Increased overall mortality (HR 1.22, p = 0.04) |
No difference | No difference |